AI-Driven Digital Cytology: Cancer Cells Have Nowhere to Hide
Quantitative and qualitative data from our AI-powered computational platform enhances cytology insights to improve workflows and quality of patient care in the battle against cancer.
Schedule Your Personalized Demo
Manual Cytology Tools Are Inadequate
Traditional cytology methods haven’t meaningfully advanced to reduce the devastation of a cancer diagnosis or recurrence. Shortcomings include:
- Missed high-risk cells
- Qualitative “gut feeling”
- Inconsistency
- Low Positive Predictive Values (PPV)
Providers often compensate through invasive, expensive, and often painful or uncomfortable procedures such as cystoscopies.
Patient aversion to these procedures can delay or interrupt treatment.
The cancer worsens or returns. Cytology samples yield inadequate insights. The devastating cycle continues.
Smart Cytology: Distinctly Advanced, Powerfully Robust
It’s time to break the cycle of flawed cancer diagnostic and management workflows
AI-empowered digital cytology from AIxMed represents a fresh, advanced approach. Our platform helps to:
- Reduce risk of missing out on suspicious cells
- Quantify and qualify suspicious and atypical cells
- Instantly share digital data
- Reduce hardships for patients, providers, cytologists, cytopathologists, and payers
- Reduce the frequency of uncomfortable and invasive procedures
- Increase PPV and aid decision support
- Streamline treatment and reduce overall healthcare costs
AIxURO is currently in FDA regulatory clearance. Clinical studies with hospitals and major collaborations are in process.
Smart Cytology: Technology Integration Throughout
Integrate the AI-powered computational platform from AIxMed to enhance and ease your current cytology workflow.
Welcome to Quantitative and Qualitative Cytology Insights
AIxMed’s AI-powered computational platform combines advanced machine learning with computer vision to discover deep insights in cytology samples.
- Rapidly digitize 3D cytology samples
- Extract meaningful, data-driven insights
- Support high-quality patient care like never before
About Our AI Technology
Cancer Cytopathology Article
An evaluation of our AIxURO platform was published in Cancer Cytopathology. AIxURO was shown to support the clinical workflow of urine cytology reporting based on The Paris System (TPS) criteria. The platform demonstrated excellent performance in the test dataset from bladder cancer patients.
AIxURO is currently in FDA regulatory clearance.
- 5.1% more sensitive than conventional methods
- 2.0% increase in NPV compared to conventional methods
- Comparable specificity and PPV to conventional methods
See the paper at Cancer Cytopathology
Digital Cytology from AIxMed is the Robust Choice
AIxMed AI-EMPOWERED DIGITAL CYTOLOGY |  |  MANUAL CYTOLOGY METHODS |
|---|---|---|
| Identify suspicious and atypical cells in multiple layers | RISK | Screen for suspicious cells Time consuming when prep is dense or scant |
| Quantitative and qualitative data | RISK | Qualitative and quantitative findings based on user experience and variability |
| Automated speed and consistency | RISK | Glass logistics and transportation |
| Annotate and interact with the same cell | TIME | Manually dotting of suspicious cell |
| Whole slide imaging | TIME | Microscopic slide review |
| Instant scalability without extra manpower | MONEY | Hire additional cytologist labor |
Our Digital Cytology Platform Targets Devastating Cancers
Data-Driven Pathology to Benefit All Stakeholders
AIxMed’s digital cytology solutions are as much about enhancing workflow efficiencies as they are about improving patient care and outcomes when battling cancer.
Pathologists
- Whole slide imaging
- More slides, less time, fewer reviewers
- Reduce bottlenecks and turnaround times
- Reallocate labor
- Confidence in results
Providers
- Reduced labor-intensive workloads
- Confidence in diagnosis, monitoring, and treatment
- Catch and treat earlier-stage cancers
- High-quality patient care
Payers
- Cost-effective
- High-quality patient care
Patients
- Comfortable sample collection
- Supports personalized patient care
- Catch and treat earlier-stage cancers